HRMY vs PFE

Harmony Biosciences maintains a strong core business anchored by WAKIX, with 2026 revenue guidance reiterated at $1.0-$1.04 billion, indicating continued market penetration and robust growth (21.1% YoY revenue growth in Q4 2025). The company's attractive valuation (P/E 11.84, PEG 0.43) and strong average annual earnings growth (32.6%) suggest undervaluation relative to its sector. However, the sig...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...